Backs the full 40% first tranche at $229.28 now — the 50-day SMA has risen every day, RSI is neutral at 53, and lighter Oct 9 volume (84.5M vs 118.7M) signals seller exhaustion, not fresh distribution. Waiting for a reclaim at $231.50 just means paying more for the same signal.
Wants the full staged plan toward ~125% of a standard position — no leverage, stops at $210.64 and a review line at $221.94 — arguing opportunity cost of being underweight is the bigger risk in the room.
Agrees the long-term uptrend and fundamentals justify a buy, but argues the first tranche should not be the largest one at the least-confirmed entry — proposes ~25–30% now, ~40–45% on a confirmed 10-EMA/VWMA reclaim with the MACD histogram turning up, and the final ~25–30% on a close above $239.24.
Targets total size closer to ~100% of a standard position (stretch to ~110% only with genuinely high risk tolerance), using $221.94 as the active risk line and $210.64 as the catastrophe backstop.
Does not dispute the fundamentals but argues buying beneath the 10-EMA/VWMA with the MACD histogram collapsing and the heaviest distribution volume since August is front-running the tape, not managing risk — a stop 8% away at $210.64 can gap through in a high-beta (2.22), geopolitically exposed name.
Recommends at most a 25% starter tranche with an active invalidation at the 50-day SMA ($221.94), capping total target at 100% (not 125%) until institutional news flow and the macro picture (Fed, Iran/oil, midterms) clarify.
Thesis: The debate produced a clean split of victories. On direction, the bull won decisively on evidence rather than assertion: quarterly revenue went from $46.7B to $96.2B in four quarters (+106% YoY) with EPS from $1.08 to $2.46 and six consecutive beats, and a 75% gross margin sustained at a $96B quarterly run-rate is the hardest number in the debate for the bear to explain away. Demand corroboration is concrete and third-party — SpaceX's $40B chip commitment, Samsung's record HBM guidance, hyperscaler capex still making new highs, and only 6% market-implied odds of an AI bubble in 2026. The balance sheet ($62.5B cash vs $38.4B debt, $102.7B operating cash flow) converts the bear's worst cases from solvency threats into valuation shocks — even a fall to $210 leaves the forward P/E around 13x. That said, the bear was right about the immediate tape: price sits below the 10-EMA and VWMA for the first time since the rally began, the MACD histogram collapsed from +1.26 to +0.12, and the Oct 8 decline printed the heaviest volume since late August — real distribution, not a non-event. Sequential growth is also genuinely decelerating (+22.0% → +17.9%), and the receivables/inventory doubling is a legitimate working-capital wedge to monitor.
Action: Build with discipline, not conviction-size at an unconfirmed entry — keep any existing position (do not trim on this pullback), and build toward ~100% of a standard single-name weight (stretch to ~110% only with high risk tolerance and no existing NVDA/semis concentration) in tranches: ~25–30% starter at ~$229 now, ~40% on a confirmed daily close back above the 10-EMA/VWMA zone (~$231.50–$231.70) with the MACD histogram turning up, or an accelerated second-tranche add if price tests and holds the 50-day SMA at $221.94 on a closing basis with selling volume continuing to dry up; the final ~25–30% only on a close back above ~$239. A decisive daily close below $221.94 cuts the starter and moves the position to review; a close below $210.64 invalidates the bull structure — exit or cut to a minimal core. No leverage or margin against the position. Re-underwrite at next earnings: sequential growth holding ≥~15%, gross margin at ~75%, and receivables/inventory not growing materially faster than revenue.